BioCentury
ARTICLE | Company News

Nabriva gets first approval in novel antibiotic class

August 19, 2019 10:50 PM UTC

Nabriva plans to launch its first approved antibiotic, Xenleta lefamulin, in mid-September to treat community-acquired bacterial pneumonia, and the company has taken steps to facilitate Xenleta's adoption through negotiations with healthcare providers, payers and pharmacies.

FDA approved on Monday a pair of NDAs from Nabriva Therapeutics plc (NASDAQ:NBRV) for IV and oral Xenleta, which represent a new antibacterial class that blocks protein synthesis by binding the peptidyl transferase center of bacterial ribosomes. On a conference call Monday, CEO Ted Schroeder noted it is the first antibiotic from a new class approved for community-acquired bacterial pneumonia in almost 20 years...

BCIQ Company Profiles

Nabriva Therapeutics plc